NCT05468307View on ClinicalTrials.gov

Study on TIL Engineered With Membrane-Binding Cytokine for the Treatment of Advanced Gynecologic Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

March 10, 2025

Study Completion Date

March 10, 2025

Conditions
Advanced Gynecologic TumorsTIL Engineered With Membrane-Binding CytokineTreatment Side EffectsEffects of Immunotherapy
Interventions
BIOLOGICAL

Membrane Bound Cytokine Modified TIL

Adoptive transfer of 2x10\^8-1x10\^10 autologous TIL engineered with membrane-binding cytokine to patients i.v. in 30-120 minutes.

Trial Locations (1)

200000

RECRUITING

Shanghai Tenth People's Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai 10th People's Hospital

OTHER

lead

Shanghai Juncell Therapeutics

INDUSTRY